Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety and efficacy of temsirolimus as a
single drug, and of temsirolimus in combination with irinotecan in chemotherapy resistant
patients with KRAS mutated colorectal cancer.